project id: TCGA-BLCA; case submitter id: TCGA-XF-AAME; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 2.0; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.52; rna integrity number: 7.1; age at index: 64; days to birth: -23448; days to death: 2828; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1942; year of death: 2013; age at diagnosis: 23448; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2006; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2877; days to sample procurement: 0; initial weight: 250.0; portion submitter id: TCGA-XF-AAME-01A-12; percent lymphocyte infiltration: 10.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 35.0; percent tumor cells: 65.0; percent tumor nuclei: 65.0;